The clinical research enterprise in critical care: What's right, what's wrong, and what's ahead?

Critical Care Medicine

Volumn 37, Issue SUPPL. 1, 2009, Pages

  Reade, Michael C ^a   Angus, Derek C ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Intensive care; Phase II; Phase III; Priority; Research

Indexed keywords

CLINICAL RESEARCH; CLINICAL STUDY; EVIDENCE BASED MEDICINE; INTENSIVE CARE; MEDICAL PRACTICE; METHODOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REVIEW; SCIENCE; SCIENTIST; ARTICLE; CLINICAL TRIAL; FINANCIAL MANAGEMENT; HUMAN; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CRITICAL CARE; EVIDENCE-BASED MEDICINE; HUMANS; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC;

EID: 58849099213     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318192074c     Document Type: Editorial

References (93)

1. Kress JP, Pohlman AS, O'Connor MF, et al: Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342: 1471-1477
2. Ely EW, Baker AM, Dunagan DP, et al: Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med 1996; 335: 1864-1869
3. Drakulovic MB, Torres A, Bauer TT, et al: Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: A randomised trial. Lancet 1999; 354:1851-1858
4. Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377
5. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342: 1301-1308
6. Holzer M, Bernard SA, Hachimi-Idrissi S, et al: Hypothermia for neuroprotection after cardiac arrest: Systematic review and individual patient data meta-analysis. Crit Care Med 2005; 33:414-418
7. Hebert PC, Wells G, Blajchman MA, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-417
8. Harvey S, Harrison DA, Singer M, et al: Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): A randomised controlled trial. Lancet 2005; 366: 472-477
9. Sandham JD, Hull RD, Brant RF, et al: A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348:5-14
10. Richard C, Warszawski J, Anguel N, et al: Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: A randomized controlled trial. JAMA 2003; 290: 2713-2720
11. Wheeler AP, Bernard GR, Thompson BT, et al: Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213-2224
12. Bellomo R, Chapman M, Finfer S, et al: Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356:2139-2143
13. Costa V, Brophy JM: Drotrecogin alfa (activated) in severe sepsis: A systematic review and new cost-effectiveness analysis. BMC Anesthesiol 2007; 7:5
14. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
15. Hornberger J, Wrone E: When to base clinical policies on observational versus randomized trial data. Ann Intern Med 1997; 127: 697-703
16. Vincent JL, Baron JF, Reinhart K, et al: Anemia and blood transfusion in critically ill patients. JAMA 2002; 288:1499-1507
17. Graf J, Doig GS, Cook DJ, et al: Randomized, controlled clinical trials in sepsis: Has methodological quality improved over time? Crit Care Med 2002; 30:461-472
18. Cook D, Finfer S: Organizing clinical critical care research and implementing the results. In: Intensive Care Medicine in 10 Years. Fink MP, Suter PM, Sibbald WJ (Eds). Berlin, Springer-Verlag, 2006, pp 311-323
19. Curtis JR, Rubenfeld GD, Hudson LD: Training pulmonary and critical care physicians in outcomes research: Should we take the challenge? Am J Respir Crit Care Med 1998; 157: 1012-1015
20. Chandler E, Langford P: Are there more critical care physicians today? 2006. Available at: http://www.sccm.org/SCCM/Publications/ Critical+Connections/ Archives/June+2006/ workforce-June06.htm. Accessed October 15, 2007
21. MacDonald R: Survey shows serious shortage of medical academics in the UK. BMJ 2002; 324:446
22. Richardson JD, Franklin GA, Rodriguez JL: Can we make training in surgical critical care more attractive? J Trauma 2005; 59: 1247-1248
23. Riedemann NC, Guo RF, Ward PA: The enigma of sepsis. J Clin Invest 2003; 112: 460-467
24. Reade MC, Young JD: Of mice and men (and rats): Implications of species and stimulus differences for the interpretation of studies of nitric oxide in sepsis. Br J Anaesth 2003; 90:115-118
25. Farmer MR, Roberts RE, Gardiner SM, et al: Effects of in vivo lipopolysaccharide infusion on vasoconstrictor function of rat isolated mesentery, kidney, and aorta. J Pharmacol Exp Ther 2003; 306:538-545
26. Traber DL: Expired nitric oxide and shock in higher order species. Crit Care Med 1999; 27:255-256
27. Sung NS, Crowley WF Jr, Genel M, et al: Central challenges facing the national clinical research enterprise. JAMA 2003; 289: 1278-1287
28. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247
29. Abraham E: Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28: S31-S33
30. Panacek EA, Marshall JC, Albertson TE, et al: Efficacy and safety of the monoclonal antitumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182
31. Gallagher J, Fisher C, Sherman B, et al: A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. Intensive Care Med 2001; 27:1169-1178
32. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-742
33. Jaimes FA: MONARCS. Statistical or clinical meaning? Crit Care Med 2005; 33:2144-2146
34. Angus DC, Crowther MA: Unraveling severe sepsis: Why did OPTIMIST fail and what's next? JAMA 2003; 290:256-258
35. Kellum JA, Kong L, Fink MP, et al: Understanding the inflammatory cytokine response in pneumonia and sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) study. Arch Intern Med 2007; 167: 1655-1663
36. FDA unveils critical path opportunities. US Food and Drug Administration. 2007. Available at: http://www.fda.gov/bbs/topics/news/ 2006/NEW01336.html. Accessed September 24, 2007
37. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: Cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-607
38. Michaelis LC, Ratain MJ: Phase II trials published in 2002: A cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clin Cancer Res 2007; 13:2400-2405
39. Chabner B: Phase II cancer trials: Out of control? Clin Cancer Res 2007; 13: 2307-2308
40. Zia MI, Siu LL, Pond GR, et al: Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 2005; 23:6982-6991
41. Ferguson ND, Kacmarek RM, Chiche JD, et al: Screening of ARDS patients using standardized ventilator settings: Influence on enrollment in a clinical trial. Intensive Care Med 2004; 30:1111-1116
42. Pittet D, Thievent B, Wenzel RP, et al: Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. Am J Respir Crit Care Med 1996; 153: 684-693
43. Vincent JL, Sakr Y, Sprung CL, et al: Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006; 34: 344-353
44. Linde-Zwirble WT, Angus DC: Severe sepsis epidemiology: Sampling, selection, and society. Crit Care 2004; 8:222-226
45. Wunsch H, Angus DC: International comparisons of intensive care: Understanding the differences. In: Yearbook of Intensive Care and Emergency Medicine. Vincent JL (Ed). Berlin, Springer-Verlag, 2006, pp 787-793
46. The Australian and New Zealand Intensive Care Society Clinical Trials Group. 2007. Available at: http://www.anzics.com.au/ctg/
47. Canadian Critical Care Trials Group. 2005. Available at: http://www.ccctg.ca/index.php
48. The NHLBI Acute Respiratory Distress Syndrome Network. 2007. Available at: http:// www.ardsnet.org
49. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367
50. Angus DC, Abraham E: Intensive insulin therapy in critical illness. Am J Respir Crit Care Med 2005; 172:1358-1359
51. Peake S, Webb S, Delaney A: Early goal-directed therapy of septic shock: We honestly remain skeptical. Crit Care Med 2007; 35: 994-995
52. Eichacker PQ, Gerstenberger EP, Banks SM, et al: Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes. Am J Respir Crit Care Med 2002; 166:1510-1514
53. Bushnell CD, Goldstein LB: Physician knowledge and practices in the evaluation of coagulopathies in stroke patients. Stroke 2002; 33:948-953
54. Henry K, Campbell S, Maki M: A comparison of observed and self-reported compliance with universal precautions among emergency department personnel at a Minnesota public teaching hospital: Implications for assessing infection control programs. Ann Emerg Med 1992; 21:940-946
55. Aday LA: Designing and Conducting Health Surveys. San Francisco, CA, John Wiley & Sons, 1996
56. Mitchell I, Finfer S, Bellomo R, et al: Management of blood glucose in the critically ill in Australia and New Zealand: A practice survey and inception cohort study. Intensive Care Med 2006; 32:867-874
57. Hebert PC, Wells G, Martin C, et al: A Canadian survey of transfusion practices in critically ill patients. Transfusion Requirements in Critical Care Investigators and the Canadian Critical Care Trials Group. Crit Care Med 1998; 26:482-487
58. McIntyre LA, Fergusson D, Cook DJ, et al: Resuscitating patients with early severe sepsis: A Canadian multicentre observational study [Reanimation des patients en debut de sepsie severe: une etude observationnelle multi-centrique canadienne]. Can J Anaesth 2007; 54:790-798
59. Vincent JL: Endpoints in sepsis trials: More than just 28-day mortality? Crit Care Med 2004; 32:S209-S213
60. Cohen J, Guyatt G, Bernard GR, et al: New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med 2001; 29:880-886
61. Laupland KB, Zygun DA, Doig CJ, et al: One-year mortality of bloodstream infectionassociated sepsis and septic shock among patients presenting to a regional critical care system. Intensive Care Med 2005; 31: 213-219
62. Yende S, Angus DC, Ali IS, et al: Influence of comorbid conditions on long-term mortality after pneumonia in older people. J Am Geriatr Soc 2007; 55:518-525
63. Wood KA, Huang D, Angus DC: Improving clinical trial design in acute lung injury. Crit Care Med 2003; 31:S305-S311
64. Angus DC, Linde-Zwirble WT, Clermont G, et al: Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003; 31:1-11
65. Bartlett RH, Roloff DW, Cornell RG, et al: Extracorporeal circulation in neonatal respiratory failure: A prospective randomized study. Pediatrics 1985; 76:479-487
66. Hornberger J, Eghtesady P: The cost-benefit of a randomized trial to a health care organization. Control Clin Trials 1998; 19: 198-211
67. Hatton J, Rapp RP, Kudsk KA, et al: Intravenous insulin-like growth factor-I (IGF-I) in moderate-to-severe head injury: A phase II safety and efficacy trial. J Neurosurg 1997; 86:779-786
68. Reinhart K, Meier-Hellmann A, Beale R, et al: Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected gram-negative sepsis. Crit Care Med 2004; 32:1662-1668
69. Conrad SA, Zwischenberger JB, Grier LR, et al: Total extracorporeal arteriovenous carbon dioxide removal in acute respiratory failure: A phase I clinical study. Intensive Care Med 2001; 27:1340-1351
70. Fort P, Farmer C, Westerman J, et al: High-frequency oscillatory ventilation for adult respiratory distress syndrome - A pilot study. Crit Care Med 1997; 25:937-947
71. Parker MR, Willatts SM: A pilot study to investigate the effects of an infusion of aminophylline on renal function following major abdominal surgery. Anaesthesia 2001; 56: 670-675
72. Siobal MS, Kallet RH, Kivett VA, et al: Use of dexmedetomidine to facilitate extubation in surgical intensive-care-unit patients who failed previous weaning attempts following prolonged mechanical ventilation: A pilot study. Respir Care 2006; 51:492-496
73. Morin K, Rakatansky H, Riddick FA Jr, et al: Managing conflicts of interest in the conduct of clinical trials. JAMA 2002; 287:78-84
74. Guyatt G: A randomized control trial of right-heart catheterization in critically ill patients. Ontario Intensive Care Study Group. J Intensive Care Med 1991; 6:91-95
75. Cox K: Enhancing cancer clinical trial management: Recommendations from a qualitative study of trial participants' experiences. Psychooncology 2000; 9:314-322
76. Coppolino M, Ackerson L: Do surrogate decision makers provide accurate consent for intensive care research? Chest 2001; 119: 603-612
77. Dumville JC, Watson J, Raynor P, et al: Research governance: A barrier to ethical research? QJM 2004; 97:113-114
78. Chalmers I: The Cochrane collaboration: Preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann N Y Acad Sci 1993; 703:156-163
79. Ghersi D, Simes J, Berlin JA: Cochrane Collaboration - Prospective Meta-analysis Methods Group. 2007. Available at: http://www. cochrane.org/docs/pma.htm
80. Silvestri L, van Saene HK, Milanese M, et al: Selective decontamination of the digestive tract reduces bacterial bloodstream infection and mortality in critically ill patients. Systematic review of randomized, controlled trials. J Hosp Infect 2007; 65:187-203
81. Cook D, Crowther MA, Douketis J: Thromboprophylaxis in medical-surgical intensive care unit patients. J Crit Care 2005; 20: 320-323
82. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
83. Carlbom DJ, Rubenfeld GD: Barriers to implementing protocol-based sepsis resuscitation in the emergency department - Results of a national survey. Crit Care Med 2007; 35:2525-2532
84. Rich MW: From clinical trials to clinical practice: Bridging the GAP. JAMA 2002; 287: 1321-1323
85. Cabana MD, Rand CS, Powe NR, et al: Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282:1458-1465
86. Eichacker PQ, Natanson C, Danner RL: Surviving sepsis - Practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006; 355:1640-1642
87. Barber JA, Thompson SG: Analysis and interpretation of cost data in randomised controlled trials: Review of published studies. BMJ 1998; 317:1195-1200
88. Doshi JA, Glick HA, Polsky D: Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. Value Health 2006; 9:334-340
89. Detsky AS, Laupacis A: Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA 2007; 298:221-224
90. Zisson S: Anticipating a clinical investigator shortfall. CenterWatch 2001; 8:1
91. Tugwell P: Campaign to revitalise academic medicine kicks off. BMJ 2004; 328:597
92. Weinert CR, Billings J, Ryan R, et al: Academic and career development of pulmonary and critical care physician-scientists. Am J Respir Crit Care Med 2006; 173:23-31
93. Marini JJ, Dries DJ: ICU research - One decade from now. In: Intensive Care Medicine in 10 Years. Fink MP, Suter PM, Sibbald WJ (Eds). Berlin, Springer-Verlag, 2006, pp 291-289